top of page
CELL4CURE
PERSONALIZED TOLERANCE
Cell4Cure AB is a Swedish, privately held cell therapy company committed to the development of treatments by inducing immune tolerance. The company’s proprietary technology platform is based on dendritic cells mediating antigen-specific tolerance, and are intended for the prevention or cure of diseases where the immune system is the enemy.
The company’s first clinical study, Toler8, is focusing on inducing tolerance to FVIII thereby preventing the occurrence of FVIII inhibitors in hemophilia A patients.
Cell4Cure will as a first step deliver value to patients and shareholders by advancing this program to clinical proof of concept.
bottom of page